Servier: contract agency email suggested increased GP call frequency (AUTH/1890/9/06)

📅 2006 | 🖉 Dr Anzal Qurbain
📊

Key facts

Case numberAUTH/1890/9/06
PartiesContract Representative v Servier Laboratories Ltd
IssueRepresentative call rates / risk of overcalling
Complaint received20 September 2006
Case completed24 November 2006
Applicable Code year2006
Breach clausesClause 15.9
No breach clauses consideredClause 15.4; Clause 2
Key evidence15 September 2006 agency email stating reps would be “required to see [targets] at increased frequency”; lack of written retraction to field force noted by Panel
AppealNo appeal
SanctionsUndertaking received; Additional sanctions: Not stated

Download the full case report (PDF)


Reviewed by Dr Anzal Qurbain (FFPM) — ABPI Final Signatory

🤖

Got a question about this case?

Ask one of our 13 specialist ABPI advisors — instant answers, 24/7.

Ask AskAnzal AI
🎬 Expert Video Walkthrough
🎬
Video walkthrough — coming for members
Subscribe now and get expert video analysis for every case as we publish them.
Subscribe — from £299/yr
📋

What happened

  • A contract representative complained that Servier’s contract sales activity effectively required some GPs to be visited up to six times before Christmas, which they believed exceeded the Code’s normal limit for unsolicited calls.
  • The Panel considered supplementary information that calls to a doctor/prescriber should not normally exceed three per year on average (excluding group meetings, requested visits, and adverse reaction follow-up).
  • On 15 September 2006, the contract representative agency emailed reps in territories with fewer than 50 target GPs, stating they would be “required to see them at increased frequency”.
  • On 21 September, after discussion with Servier, the agency told sales managers more doctors would be added to target lists so overcalling would not be necessary; the Panel was concerned there were no written instructions sent to the field force retracting the earlier “increased frequency” message.
  • The Panel found no evidence that overcalling had actually occurred.
⚖️

Outcome

  • Breach of Clause 15.9 was ruled because the 15 September email advocated a course of action likely to breach the Code.
  • No breach of Clause 15.4 was ruled because there was no evidence that overcalling had actually occurred.
  • No breach of Clause 2 was ruled; the Panel did not consider the matter sufficiently serious for that level of censure.
  • No appeal.
🔒

Unlock the full case analysis

Members get the complete breakdown — Clauses, Sanction, Signatory Lens, Audit checklist, and 3 Key Questions.

Best value
£249/year
Annual — save £99
or
£29/mo
Monthly
Join Now — Instant Access

⭐ Business Intelligence Access

See the full compliance picture for every pharma company

291 Company Intelligence Reports — breach patterns, appeal history, industry ranking, PDF export.

Request Access →
⭐ Flagship Programme

AQP Flagship Path — the complete UK ABPI signatory programme

12 modules. 12 weeks. Final Signatory readiness. The industry standard for ABPI Code signatories — £995 + VAT.

Enrol — AQP Path Learn more

📰 Weekly PMCPA Case Breakdown

One real case. One key lesson. Every week — free.

Subscribe Free
🎓 AQP Training